Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

Market Cap	8.29B +82.1%
Revenue (ttm)	1.31B +22.2%
Net Income	3.93M
EPS	0.01
Shares Out	538.65M
PE Ratio	2,108.74
Forward PE	11.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,832,794
Open	15.30
Previous Close	15.30
Day's Range	15.22 - 15.68
52-Week Range	8.60 - 22.63
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,663
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300497

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -55.03 million, -79.78% less than in 2024.